Jupiter Neurosciences Receives Dual Nasdaq Delisting Notices for Bid Price and Market Value Deficiencies
JUNS is trading near its 52-week low of $0.48 (4.2% above the low) on light trading volume (0.2× avg).
Summary
Jupiter Neurosciences, Inc. received notices from Nasdaq for failing to meet both the minimum $1.00 bid price and the $35 million market value of listed securities requirements, initiating a 180-day compliance period to avoid delisting.
Key Events · Corporate Governance and Compliance · JUNS
-
Dual Nasdaq Delisting Notices Received
On February 26, 2026, Jupiter Neurosciences, Inc. received two written notices from Nasdaq Stock Market LLC regarding non-compliance with continued listing rules.
-
Minimum Bid Price Deficiency
The company's common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
-
Market Value of Listed Securities (MVLS) Deficiency
The company's market value of listed securities closed below the $35 million threshold for 30 consecutive business days, violating Nasdaq Listing Rule 5550(b)(2).
-
180-Day Compliance Period
The company has 180 calendar days, until August 25, 2026, to regain compliance with both the Minimum Bid Price Requirement and the MVLS Requirement.
Analysis · JUNS · Life Sciences
Jupiter Neurosciences, Inc. faces significant uncertainty regarding its Nasdaq listing after receiving two notices of non-compliance. The company failed to meet both the minimum $1.00 bid price and the $35 million market value of listed securities (MVLS) requirements. With a current market capitalization of approximately $18.2 million, the MVLS deficiency presents a substantial challenge, requiring the company to more than double its market value within 180 days. This situation, coupled with the stock trading near its 52-week low, indicates severe financial distress and poses a material risk to the company's ability to maintain its public listing, which is crucial for liquidity and investor confidence. Investors should monitor the company's progress in addressing these deficiencies, particularly any plans for a reverse stock split, which is often a last resort to meet bid price requirements but does not address underlying valuation issues.
At the time of this filing, JUNS was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.2M. The 52-week trading range was $0.48 to $3.33. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.